Technology 2018-10-03T20:58:34+00:00

Emerald Health Pharmaceuticals (EHP) is developing new drugs that leverage the known benefits of cannabinoid interaction with the human endocannabinoid system (ECS) to positively impact central nervous system (CNS), auto-immune, inflammatory, metabolic, and fibrotic diseases. Starting from cannabinoids, we target the ECS and other relevant receptors that may provide valuable therapeutic benefits against these deadly diseases.

EHP’s scientists have chemically modified non-psychotropic cannabinoids to affect additional validated biological targets and physiologic pathways. The resulting drug candidates have been shown in validated animal models to achieve therapeutic benefits that exceed the capabilities of any of these mechanisms alone. As new chemical entities (NCEs), these molecules are protected by composition of matter patents.

Emerald’s platform technology consists of two families of synthetic cannabinoid molecules derived from cannabidiol (CBD) and cannabigerol (CBG), with over twenty patented NCEs.


CBD to EHP-101

EHP-101 is derived from CBD, the most abundant natural cannabinoid. EHP-101 has been modified to enhance the therapeutic benefits of CBD by being a dual PPARγ and CB2 agonist that also activates the hypoxia inducible factor (HIF) pathway. There is evidence that these validated receptors may be beneficial in preventing neuroinflammation and demyelination in the CNS, and fibrogenesis in the periphery. Based on these activities, Emerald is initially developing this proprietary new drug candidate for multiple sclerosis and scleroderma.


CBG to EHP-102

EHP-102 is derived from CBG, another abundant natural cannabinoid. CBG has been shown to be anti-inflammatory and shows evidence of neuroprotection. EHP-102 has been modified to provide even more potent benefits compared to CBG by also affecting PPARγ, a key molecular target for the treatment of Huntington’s disease, as well as targeting other pathways involved in neural survival. These characteristics have led EHP to develop this proprietary new drug candidate for Huntington’s disease and Parkinson’s disease.